The etiology of glomerulonephritis: Roles of infection and autoimmunity

Kidney International

Volumn 86, Issue 5, 2014, Pages 905-914

  Couser, William G ^a   Johnson, Richard J ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

chronic glomerulonephritis; clinical immunology; glomerulonephritis; immunology and pathology; inflammation

Indexed keywords

ANTIBODY; ANTIGEN; EPITOPE; AUTOANTIBODY; BACTERIUM ANTIBODY; COMPLEMENT; VIRUS ANTIBODY;

AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; C3 NEPHROPATHY; CONFORMATIONAL TRANSITION; GLOMERULONEPHRITIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOREGULATION; INFECTION; INNATE IMMUNITY; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MOLECULAR MIMICRY; NONHUMAN; PARVOVIRUS; PATHOGENESIS; POST INFECTIOUS GLOMERULONEPHRITIS; REVIEW; SYSTEMS BIOLOGY; T LYMPHOCYTE ACTIVATION; ANIMAL; BACTERIAL INFECTION; COMPLICATION; GENETIC PREDISPOSITION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; KIDNEY; MICROBIOLOGY; MICROFLORA; RISK FACTOR; VIROLOGY; VIRUS INFECTION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; AUTOANTIBODIES; AUTOIMMUNITY; BACTERIAL INFECTIONS; COMPLEMENT SYSTEM PROTEINS; GENETIC PREDISPOSITION TO DISEASE; GLOMERULONEPHRITIS; HOST-PATHOGEN INTERACTIONS; HUMANS; KIDNEY; MICROBIOTA; RISK FACTORS; VIRUS DISEASES;

EID: 84908576580     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.49     Document Type: Review

References (129)

1. Bright R. Tabular view of the morbid appearances in 100 cases connected with albuminous urine. Guys Hosp Rep 1836; 1: 338-379
2. Dixon FJ, Feldman JD, Vazquez JJ. Experimental glomerulonephritis. The pathogenesis of a laboratory model resembling the spectrum of human glomerulonephritis. J Exp Med 1961; 113: 899-920
3. Germuth FGJ, Rodriguez E. Immunopathology of the Renal Glomerulus: Immune Complex Deposit and Antibasement Membrane Disease. Little Brown and Company: Boston, 1973
4. Dixon FJ, Vazquez JJ, Weigle WO, et al. Pathogenesis of serum sickness. AMA Arch Pathol 1958; 65: 18-28
5. Couser WG. Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol 2012; 23: 381-399
6. Ponticelli C, Salvadori M, Coppo R. The kidney, a victim and culprit of autoimmune and alloimmune responses. Nephron Clin Pract 2011; 119: c200-c204
7. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300
8. Miller FW, Pollard KM, Parks CG, et al. Criteria for environmentally associated autoimmune diseases. J Autoimmun 2012; 39: 253-258
9. Choi HK, Lamprecht P, Niles JL, et al. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum 2000; 43: 226-231
10. La Civita L, Fadda P, Olivieri I, et al. Cryoglobulinaemic vasculitis as presenting manifestation of infective endocarditis. Ann Rheum Dis 2002; 61: 89-90
11. Lane SK, Gravel JW Jr. Clinical utility of common serum rheumatologic tests. Am Fam Physician 2002; 65: 1073-1080
12. Spruss A, Bergheim I. Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J Nutr Biochem 2009; 20: 657-662
13. Pollard KM, Kono DH. Requirements for innate immune pathways in environmentally induced autoimmunity. BMC Med 2013; 11: 100
14. Waldmann H. Tolerance: an overview and perspectives. Nat Rev Nephrol 2010; 6: 569-576
15. Jennette JC, Falk RJ. The rise and fall of horror autotoxicus and forbidden clones. Kidney Int 2010; 78: 533-535
16. Pillai S. Rethinking mechanisms of autoimmune pathogenesis. J Autoimmun 2013; 45: 97-103
17. Chiang CK, Inagi R. Glomerular diseases: genetic causes and future therapeutics. Nat Rev Nephrol 2010; 6: 539-554
18. Romo-Tena J, Gomez-Martin D, Alcocer-Varela J. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev 2013; 12: 1171-1176
19. Gatto M, Zen M, Ghirardello A, et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013; 12: 523-536
20. Phelps RG, Rees AJ. The HLA complex in Goodpastures disease: a model for analyzing susceptibility to autoimmunity. Kidney Int 1999; 56: 1638-1653
21. Salama AD, Chaudhry AN, Holthaus KA, et al. Regulation by CD25- lymphocytes of autoantigen-specific T-cell responses in Goodpastures (anti-GBM) disease. Kidney Int 2003; 64: 1685-1694
22. Gravano DM, Hoyer KK. Promotion and prevention of autoimmune disease by CD8- T cells. J Autoimmun 2013; 45: 68-79
23. Seredkina N, Van Der Vlag J, Berden J, et al. Lupus nephritis: enigmas, conflicting models and an emerging concept. Mol Med 2013; 19: 161-169
24. Free ME, Bunch DO, McGregor JA, et al. Patients with antineutrophil cytoplasmic antibody-Associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum 2013; 65: 1922-1933
25. Morgan MD, Day CJ, Piper KP, et al. Patients with Wegeners granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology 2010; 130: 64-73
26. Araya C, Diaz L, Wasserfall C, et al. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol 2009; 24: 1691-1698
27. Sellin CI, Jegou JF, Renneson J, et al. Interplay between virus-specific effector response and Foxp3 regulatory T cells in measles virus immunopathogenesis. PLoS ONE 2009; 4: e4948
28. Kincaid RP, Sullivan CS. Virus-encoded microRNAs: an overview and a look to the future. PLoS Pathog 2012; 8: e1003018
29. Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol 2012; 42: 102-111
30. Harkiolaki M, Holmes SL, Svendsen P, et al. T cell-mediated autoimmune disease due to low-Affinity crossreactivity to common microbial peptides. Immunity 2009; 30: 348-357
31. Kaplan MH, Svec KH. Immunologic relation of streptococcal and tissue antigens. Iii. Presence in human sera of streptococcal antibody cross-reactive with heart tissue. Association with streptococcal infection, rheumatic fever, and glomerulonephritis. J Exp Med 1964; 119: 651-666
32. Rejholec V, Wagner V. Response by antibodies to tissue antigens in the course of rheumatic fever. Ann Rheum Dis 1956; 15: 364-372
33. Arends J, Wu J, Borillo J, et al. T cell epitope mimicry in antiglomerular basement membrane disease. J Immunol 2006; 176: 1252-1258
34. Pendergraft WF 3rd, Preston GA, Shah RR, et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10: 72-79
35. Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14: 1088-1096
36. Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013; 382: 819-831
37. Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol 2013; 24: 1357-1366
38. Pollard KM, Cauvi DM, Toomey CB, et al. Interferon-gamma and systemic autoimmunity. Discov Med 2013; 16: 123-131
39. Ju T, Wang Y, Aryal RP, et al. Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers. Proteomics Clin Appl 2013; doi: 10.1002/prca.201300024 (e-pub ahead of print
40. Luo YH, Chuang WJ, Wu JJ, et al. Molecular mimicry between streptococcal pyrogenic exotoxin B and endothelial cells. Lab Invest 2010; 90: 1492-1506
41. Acha-Orbea H. Bacterial and viral superantigens: roles in autoimmunity? Ann Rheum Dis 1993; 52(Suppl 1): S6-16
42. Spaulding AR, Salgado-Pabon W, Kohler PL, et al. Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev 2013; 26: 422-447
43. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-521
44. Murali-Krishna K, Altman JD, Suresh M, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998; 8: 177-187
45. Tadema H, Abdulahad WH, Lepse N, et al. Bacterial DNA motifs trigger ANCA production in ANCA-Associated vasculitis in remission. Rheumatology 2011; 50: 689-696
46. Anaya JM. Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmun Rev 2012; 11: 781-784
47. McKee AS, Burchill MA, Munks MW, et al. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc Natl Acad Sci USA 2013; 110: E1122-E1131
48. Lambert PH, Dixon FJ. Genesis of antinuclear antibody in NZB-W mice: role of genetic factors and of viral infections. Clin Exp Immunol 1970; 6: 829-839
49. Kalluri R, Cantley LG, Kerjaschki D, et al. Reactive oxygen species expose cryptic epitopes associated with autoimmune goodpasture syndrome. J Biol Chem 2000; 275: 20027-20032
50. Pedchenko V, Bondar O, Fogo AB, et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 2010; 363: 343-354
51. Szilagyi A, Kiss N, Bereczki C, et al. The role of complement in Streptococcus pneumoniae-Associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2013; 28: 2237-2245
52. Mikuls TR, Thiele GM, Deane KD, et al. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum 2012; 64: 3522-3530
53. Maresz KJ, Hellvard A, Sroka A, et al. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). PLoS Pathog 2013; 9: e1003627
54. Delogu LG, Deidda S, Delitala G, et al. Infectious diseases and autoimmunity. J Infect Dev Ctries 2011; 5: 679-687
55. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85-95
56. Hudson BG. The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J Am Soc Nephrol 2004; 15: 2514-2527
57. Robertson J, Wu J, Arends J, et al. Characterization of the T-cell epitope that causes anti-GBM glomerulonephritis. Kidney Int 2005; 68: 1061-1070
58. Zhao J, Cui Z, Yang R, et al. Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity. Kidney Int 2009; 76: 1108-1115
59. Chen JL, Hu SY, Jia XY, et al. Association of epitope spreading of antiglomerular basement membrane antibodies and kidney injury. Clin J Am Soc Nephrol 2013; 8: 51-58
60. Shah P, Tramontano A, Makker SP. Intramolecular epitope spreading in Heymann nephritis. J Am Soc Nephrol 2007; 18: 3060-3066
61. Prunotto M, Carnevali ML, Candiano G, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010; 21: 507-519
62. Root-Bernstein R. Antigenic complementarity in the induction of autoimmunity: a general theory and review. Autoimmun Rev 2007; 6: 272-277
63. Yang J, Bautz DJ, Lionaki S, et al. ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int 2008; 74: 1159-1169
64. Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu Rev Immunol 2012; 30: 759-795
65. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139: 485-498
66. Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010; 32: 815-827
67. Gluba A, Banach M, Hannam S, et al. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol 2010; 6: 224-235
68. Rodriguez-Iturbe B, Batsford S. Pathogenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet. Kidney Int 2007; 71: 1094-1104
69. Rodriguez-Iturbe B, Musser JM. The current state of poststreptococcal glomerulonephritis. J Am Soc Nephrol 2008; 19: 1855-1864
70. Sesso RC, Ramos OL, Pereira AB. Detection of IgG-rheumatoid factor in sera of patients with acute poststreptococcal glomerulonephritis and its relationship with circulating immunecomplexes. Clin Nephrol 1986; 26: 55-60
71. Vilches AR, Williams DG. Persistent anti-DNA antibodies and DNA-Anti-DNA complexes in post-streptococcal glomerulonephritis. Clin Nephrol 1984; 22: 97-101
72. Ardiles LG, Valderrama G, Moya P, et al. Incidence and studies on antigenic specificities of antineutrophil-cytoplasmic autoantibodies (ANCA) in poststreptococcal glomerulonephritis. Clin Nephrol 1997; 47: 1-5
73. Luo YH, Kuo CF, Huang KJ, et al. Streptococcal pyrogenic exotoxin B antibodies in a mouse model of glomerulonephritis. Kidney Int 2007; 72: 716-724
74. Rodriguez-Iturbe B, Rabideau D, Garcia R, et al. Characterization of the glomerular antibody in acute poststreptococcal glomerulonephritis. Ann Intern Med 1980; 92: 478-481
75. Sethi S, Fervenza FC, Zhang Y, et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 2013; 83: 293-299
76. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368: 2402-2414
77. Jiang S, Chuang PY, Liu ZH, et al. The primary glomerulonephritides: a systems biology approach. Nat Rev Nephrol 2013; 9: 500-512
78. Kiryluk K, Novak J, Gharavi AG. Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies. Annu Rev Med 2013; 64: 339-356
79. Coppo R, Amore A, Peruzzi L, et al. Innate immunity and IgA nephropathy. J Nephrol 2010; 23: 626-632
80. Filiopoulos V, Trompouki S, Hadjiyannakos D, et al. IgA nephropathy in association with Crohns disease: a case report and brief review of the literature. Ren Fail 2010; 32: 523-527
81. Smith AC, Molyneux K, Feehally J, et al. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol 2006; 17: 3520-3528
82. Barratt J, Bailey EM, Buck KS, et al. Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Am J Kidney Dis 1999; 33: 1049-1057
83. Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999; 104: 73-81
84. Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009; 119: 1668-1677
85. Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012; 23: 1579-1587
86. Mestecky J, Raska M, Julian BA, et al. IgA nephropathy: molecular mechanisms of the disease. Annu Rev Pathol 2013; 8: 217-240
87. Ju T, Otto VI, Cummings RD. The Tn antigen-structural simplicity and biological complexity. Angew Chem Int Ed Engl 2011; 50: 1770-1791
88. Stuchlova Horynova M, Raska M, Clausen H, et al. Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma. Cell Mol Life Sci 2013; 70: 829-839
89. Pedchenko V, Vanacore R, Hudson B. Goodpastures disease: molecular architecture of the autoantigen provides clues to etiology and pathogenesis. Curr Opin Nephrol Hypertens 2011; 20: 290-296
90. Cui Z, Zhao MH, Segelmark M, et al. Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int 2010; 78: 590-597
91. Goodpasture EW. Landmark publication from The American Journal of the Medical Sciences: the significance of certain pulmonary lesions in relation to the etiology of influenza. Am J Med Sci 2009; 338: 148-151
92. Roth AJ, Ooi JD, Hess JJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-Associated vasculitis. J Clin Invest 2013; 123: 1773-1783
93. Bosch X. LAMPs and NETs in the pathogenesis of ANCA vasculitis. J Am Soc Nephrol 2009; 20: 1654-1656
94. Summers DM, Johnson RJ, Hudson A, et al. Effect of donor age and cold storage time on outcome in recipients of kidneys donated after circulatory death in the UK: a cohort study. Lancet 2013; 381: 727-734
95. Davies DJ, Moran JE, Niall JF, et al. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 1982; 285: 606
96. Willcocks LC, Lyons PA, Rees AJ, et al. The contribution of genetic variation and infection to the pathogenesis of ANCA-Associated systemic vasculitis. Arthritis Res Ther 2010; 12: 202
97. Tadema H, Heeringa P, Kallenberg CG. Bacterial infections in Wegeners granulomatosis: mechanisms potentially involved in autoimmune pathogenesis. Curr Opin Rheumatol 2011; 23: 366-371
98. Savige J, Pollock W, Trevisin M. What do antineutrophil cytoplasmic antibodies (ANCA) tell us? Best Pract Res Clin Rheumatol 2005; 19: 263-276
99. Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12-17
100. Fervenza FC, Specks U. Vasculitis: Will LAMP enlighten us about ANCA-Associated vasculitis? Nat Rev Nephrol 2012; 8: 318-320
101. Ciavatta DJ, Yang J, Preston GA, et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest 2010; 120: 3209-3219
102. Jennette JC, Falk RJ, Hu P, et al. Pathogenesis of antineutrophil cytoplasmic autoantibody-Associated small-vessel vasculitis. Annu Rev Pathol 2013; 8: 139-160
103. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110-2121
104. Costa-Reis P, Sullivan KE. Genetics and epigenetics of systemic lupus erythematosus. Curr Rheumatol Rep 2013; 15: 369
105. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533
106. Boackle SA. Advances in lupus genetics. Curr Opin Rheumatol 2013; 25: 561-568
107. Kulkarni OP, Anders HJ. Lupus nephritis. How latest insights into its pathogenesis promote novel therapies. Curr Opin Rheumatol 2012; 24: 457-465
108. Getts DR, Chastain EM, Terry RL, et al. Virus infection, antiviral immunity, and autoimmunity. Immunol Rev 2013; 255: 197-209
109. Green NM, Moody KS, Debatis M, et al. Activation of autoreactive B cells by endogenous TLR7 and TLR3 RNA ligands. J Biol Chem 2012; 287: 39789-39799
110. Pender MP. CD8- T-cell deficiency, Epstein-Barr virus infection, vitamin D deficiency, and steps to autoimmunity: a unifying hypothesis. Autoimmune Dis 2012; 2012: 189096
111. Draborg AH, Duus K, Houen G. Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol 2012; 2012; 370516
112. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-470
113. Sansonno L, Tucci FA, Sansonno S, et al. B cells and HCV: an infection model of autoimmunity. Autoimmun Rev 2009; 9: 93-94
114. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 2009; 76: 818-824
115. Alpers CE, Smith KD. Cryoglobulinemia and renal disease. Curr Opin Nephrol Hypertens 2008; 17: 243-249
116. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis-A new look at an old entity. N Engl J Med 2012; 366: 1119-1131
117. Lauletta G, Russi S, Conteduca V, et al. Hepatitis C virus infection and mixed cryoglobulinemia. Clin Dev Immunol 2012; 2012; 502156
118. Fabrizi F, Plaisier E, Saadoun D, et al. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis 2013; 61: 623-637
119. Cacoub P, Ghillani P, Revelen R, et al. Anti-endothelial cell autoantibodies in hepatitis C virus mixed cryoglobulinemia. J Hepatol 1999; 31: 598-603
120. Manenti L, Gnappi E, Vaglio A, et al. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrol Dial Transplant 2013; 28: 2246-2259
121. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21
122. Hofstra JM, Beck LH Jr., Beck DM, et al. Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011; 6: 1286-1291
123. Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364: 616-626
124. Ponticelli C, Glassock RJ. Glomerular diseases: membranous nephropathy-A modern view. Clin J Am Soc Nephrol 2013 (e-pub ahead of print
125. Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 2012; 8: 634-642
126. Sethi S, Fervenza FC, Zhang Y, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82: 465-473
127. Barbour TD, Pickering MC, Cook HT. Recent insights into C3 glomerulopathy. Nephrol Dial Transplant 2013; 28: 1685-1693
128. Lamb V, Tisher CC, McCoy RC, et al. Membranoproliferative glomerulonephritis with dense intramembranous alterations. A clinicopathologic study. Lab Invest 1977; 36: 607-617
129. Gewurz AT, Imherr SM, Strauss S, et al. C3 nephritic factor and hypocomplementaemia in a clinically healthy individual. Clin Exp Immunol 1983; 54: 253-258